Literature DB >> 11741909

The cyclin-dependent kinase inhibitor p21WAF1/Cip1 is an antiestrogen-regulated inhibitor of Cdk4 in human breast cancer cells.

Andrew J Skildum1, Shibani Mukherjee, Susan E Conrad.   

Abstract

The MCF-7 cell line is a model of estrogen-dependent, antiestrogen-sensitive human breast cancer. Antiestrogen treatment of MCF-7 cells causes dramatic decreases in both Cdk4 and Cdk2 activities, which leads to a G(1) phase cell cycle arrest. In this report, we investigate the mechanism(s) by which Cdk4 activity is regulated in MCF-7 cells. Through time course analysis, we demonstrate that changes in Cdk4 activity in response to estrogen or antiestrogen treatment do not correlate directly with cyclin D1 protein levels or association. In contrast, Cdk4 activity does correlate with changes in the level of the Cdk inhibitor p21(WAF1/Cip1). Furthermore, we show that extracts of antiestrogen-treated cells contain a factor capable of inhibiting the Cdk4 activity present in extracts of estrogen-treated cells, and immunodepletion experiments identify this factor as p21(WAF1/Cip1). These results identify p21(WAF1/Cip1) as an important physiological regulator of Cdk4 complexes in human breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11741909     DOI: 10.1074/jbc.M109179200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  CARM1 is an important determinant of ERα-dependent breast cancer cell differentiation and proliferation in breast cancer cells.

Authors:  Mariam Al-Dhaheri; Jiacai Wu; Georgios P Skliris; Jun Li; Ken Higashimato; Yidan Wang; Kevin P White; Paul Lambert; Yuerong Zhu; Leigh Murphy; Wei Xu
Journal:  Cancer Res       Date:  2011-01-31       Impact factor: 12.701

2.  Effect of indomethacin on cell cycle proteins in colon cancer cell lines.

Authors:  Mei-Hua Xu; Gui-Ying Zhang
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

Review 3.  Preclinical and clinical development of palbociclib and future perspectives.

Authors:  E Martínez de Dueñas; J Gavila-Gregori; S Olmos-Antón; A Santaballa-Bertrán; A Lluch-Hernández; E J Espinal-Domínguez; M Rivero-Silva; A Llombart-Cussac
Journal:  Clin Transl Oncol       Date:  2018-03-21       Impact factor: 3.405

4.  Androgen receptor as a targeted therapy for breast cancer.

Authors:  Joseph P Garay; Ben H Park
Journal:  Am J Cancer Res       Date:  2012-06-28       Impact factor: 6.166

5.  Epigenetic Dysregulation of the Dynamin-Related Protein 1 Binding Partners MiD49 and MiD51 Increases Mitotic Mitochondrial Fission and Promotes Pulmonary Arterial Hypertension: Mechanistic and Therapeutic Implications.

Authors:  Kuang-Hueih Chen; Asish Dasgupta; Jianhui Lin; François Potus; Sébastien Bonnet; James Iremonger; Jennifer Fu; Jeffrey Mewburn; Danchen Wu; Kimberly Dunham-Snary; Anne L Theilmann; Zhi-Cheng Jing; Charles Hindmarch; Mark L Ormiston; Allan Lawrie; Stephen L Archer
Journal:  Circulation       Date:  2018-02-05       Impact factor: 29.690

6.  Regulation of CDK4.

Authors:  Laurence Bockstaele; Katia Coulonval; Hugues Kooken; Sabine Paternot; Pierre P Roger
Journal:  Cell Div       Date:  2006-11-08       Impact factor: 5.130

7.  Functional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cells.

Authors:  Hemant Varma; Andrew J Skildum; Susan E Conrad
Journal:  PLoS One       Date:  2007-12-05       Impact factor: 3.240

8.  Differential and directional estrogenic signaling pathways induced by enterolignans and their precursors.

Authors:  Yun Zhu; Kayoko Kawaguchi; Ryoiti Kiyama
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

9.  A tRNA fragment, tRF5-Glu, regulates BCAR3 expression and proliferation in ovarian cancer cells.

Authors:  Kun Zhou; Kevin W Diebel; Jon Holy; Andrew Skildum; Evan Odean; Douglas A Hicks; Brent Schotl; Juan E Abrahante; Monique A Spillman; Lynne T Bemis
Journal:  Oncotarget       Date:  2017-09-08

10.  Differential control of growth, apoptotic activity, and gene expression in human breast cancer cells by extracts derived from medicinal herbs Zingiber officinale.

Authors:  Ayman I Elkady; Osama A Abuzinadah; Nabih A Baeshen; Tarek R Rahmy
Journal:  J Biomed Biotechnol       Date:  2012-08-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.